Dana-Farber Cancer Institute shared a post on LinkedIn:
“Anuj Patel, MD, recently presented research at ESMO – European Society for Medical Oncology GI, receiving a Best Poster Award for work on a new circulating tumor DNA (ctDNA) test designed to detect minimal residual disease (MRD) in patients who undergo curative treatment for locally advanced esophageal cancer.
The test, developed in collaboration with Harvey Mamon, MD, PhD, Peter Enzinger, MD, G. Mike Makrigiorgos, PhD, and Viktor Adalsteinsson, PhD of the Broad Institute of MIT and Harvard, demonstrated improved detection of MRD. Patel hopes this advancement marks a meaningful step forward in the treatment of esophageal cancer. The research was made possible through philanthropic funding.”
More posts featuring Dana-Farber Cancer Institute.